Mainz Biomed partners with TomaLab to expand availability of ColoAlert in Italy

Mainz Biomed announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert in Italy. TomaLab is one of Italy’s premier biotechnology laboratories and is based in Milan. The partnership signifies a major step forward in enhancing colorectal cancer screening and diagnostics within the Italian healthcare system as it enables the implementation of ColoAlert into Italy’s robust healthcare framework, providing patients with access to a cutting-edge diagnostic solution that combines convenience with clinical excellence. “TomaLab is the ideal partner to bring our pioneering product to Italy given its state-of-the-art facilities and commitment to innovative healthcare solutions,” said Guido Baechler, CEO of Mainz Biomed. “This collaboration aligns with our mission to make advanced diagnostic tools widely accessible, improving early detection rates and ultimately saving lives.”